New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathway.

Insight into the mechanisms of primary or acquired drug resistance of (hematological) malignancies is critical for the development of new treatment strategies. This review will focus on Bcl-2 and the mevalonate pathway as targets for reversal of drug resistance in multiple myeloma. The Bcl-2 protein is highly expressed in myeloma patients and in vitro studies have shown its role in the regulation of chemosensitivity, which makes Bcl-2 an attractive target for treatment. Statins are widely used for the treatment of hypercholesteremia. Several in vitro studies have shown that statins may also kill hematological malignant cells including myeloma cells. We found that lovastatin induced apoptosis in myeloma and lymphoma cells by inhibition of geranylgeranylation and subsequent down regulation of Mcl-1, probably the most important anti-apoptotic protein in myeloma. Phase 1 and 2 studies have been performed with Bcl-2 antisense oligonucleotides and high dose simvastatin in combination with chemotherapy in heavily pre-treated myeloma patients. Encouraging results from these studies may provide the framework for the future application of new treatment strategies for myeloma.

[1]  S. Sebti,et al.  Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies , 2000, Oncogene.

[2]  H. Garewal,et al.  Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Gelb.  Protein Prenylation, et cetera--Signal Transduction in Two Dimensions , 1997, Science.

[4]  R. Bataille,et al.  Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. , 2002, Blood.

[5]  Ziwei Huang,et al.  Bcl-2 family proteins as targets for anticancer drug design , 2000, Oncogene.

[6]  Robert L Moritz,et al.  Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins , 2000, Cell.

[7]  K. Aktories,et al.  Clostridium botulinum C3 ADP-ribosyltransferase. , 1992, Current topics in microbiology and immunology.

[8]  J. Chant,et al.  Rac and Cdc42 Induce Actin Polymerization and G1 Cell Cycle Progression Independently of p65PAK and the JNK/SAPK MAP Kinase Cascade , 1996, Cell.

[9]  V. Cryns,et al.  Proteases to die for. , 1998, Genes & development.

[10]  S. Srinivasula,et al.  Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  B. V. Van Ness,et al.  Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6. , 1997, Cancer research.

[12]  A. Bloem,et al.  Co‐Iigation of ICAM‐1 (CD54) and membrane IgM negatively affects B cell receptor signaling , 1995 .

[13]  B. Durie.  Staging and kinetics of multiple myeloma. , 1982, Seminars in oncology.

[14]  M. Urashima,et al.  IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. , 1997, Journal of immunology.

[15]  I. Gojo,et al.  Myeloid cell factor-1 is a critical survival factor for multiple myeloma. , 2002, Blood.

[16]  L. Feig,et al.  Involvement of R-Ras and Ral GTPases in estrogen-independent proliferation of breast cancer cells , 2002, Oncogene.

[17]  J. Beresford,et al.  Osteoblasts and osteoclasts in adult human osteophyte tissue express the mRNAs for insulin-like growth factors I and II and the type 1 IGF receptor. , 1995, Bone.

[18]  A. Lichtenstein,et al.  The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. , 2000, Cancer research.

[19]  Gienke R Boersma-Vreugdenhil,et al.  Translocation of the IgH locus is nearly ubiquitous in multiple myeloma as detected by immuno-FISH. , 2003, Blood.

[20]  Z. Darżynkiewicz,et al.  Cell cycle-specific effects of lovastatin. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Trudel,et al.  Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance. , 2002, Blood.

[22]  I. Pastan,et al.  Dansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells. , 1980, The Journal of biological chemistry.

[23]  H. Pehamberger,et al.  bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice , 1998, Nature Medicine.

[24]  C. Croce,et al.  Inactivation of Bcl-2 by phosphorylation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Georgii‐Hemming,et al.  Expression of the bcl‐2 family of pro‐ and anti‐apoptotic genes in multiple myeloma and normal plasma cells , 2002, European journal of haematology.

[26]  N. V. D. Donk,et al.  The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells , 2002, Leukemia.

[27]  Y. Gazitt,et al.  Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells. , 1998, International journal of oncology.

[28]  V. Dixit,et al.  Boo, a novel negative regulator of cell death, interacts with Apaf‐1 , 1999, The EMBO journal.

[29]  D. Bar-Sagi,et al.  RAC Regulation of Actin Polymerization and Proliferation by a Pathway Distinct from Jun Kinase , 1996, Science.

[30]  John Calvin Reed,et al.  BCL-X expression in multiple myeloma: possible indicator of chemoresistance. , 1998, Cancer research.

[31]  A. Krieg,et al.  CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. , 1998, Journal of immunology.

[32]  G. Ahmann,et al.  Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. , 1999, Blood.

[33]  A. Lichtenstein,et al.  Interleukin-6 inhibits apoptosis of malignant plasma cells. , 1995, Cellular immunology.

[34]  J. Epstein,et al.  P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. , 1989, Blood.

[35]  M. Minden,et al.  Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. , 1999, Blood.

[36]  D. de Jong,et al.  Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. , 1994, Cancer research.

[37]  J. Tainer,et al.  Crystal structure and novel recognition motif of rho ADP-ribosylating C3 exoenzyme from Clostridium botulinum: structural insights for recognition specificity and catalysis. , 2001, Journal of molecular biology.

[38]  R. Bataille,et al.  Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. , 1999, Blood.

[39]  C. Croce,et al.  Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. , 1996, Cancer research.

[40]  Richard LeBlanc,et al.  Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. , 2002, Blood.

[41]  A. Strasser,et al.  The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. , 1999, Molecular cell.

[42]  Channing J Der,et al.  Rho family proteins and Ras transformation: the RHOad less traveled gets congested , 1998, Oncogene.

[43]  S. Korsmeyer,et al.  Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair , 1993, Cell.

[44]  John Calvin Reed,et al.  The AKT kinase is activated in multiple myeloma tumor cells. , 2001, Blood.

[45]  L. Mayer,et al.  Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  S. Sebti,et al.  Disruption of Oncogenic K-Ras4B Processing and Signaling by a Potent Geranylgeranyltransferase I Inhibitor(*) , 1995, The Journal of Biological Chemistry.

[47]  R. Craig.  MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis , 2002, Leukemia.

[48]  M. Gleave,et al.  A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  John G. Collard,et al.  A role for Rac in Tiaml-induced membrane ruffling and invasion , 1995, Nature.

[50]  M. K. Meintzer,et al.  An Essential Role for Rac/Cdc42 GTPases in Cerebellar Granule Neuron Survival* , 2001, The Journal of Biological Chemistry.

[51]  B. Burgering,et al.  Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction , 1995, Nature.

[52]  C. Marshall,et al.  New Insights into the Interaction of Ras with the Plasma Membrane , 1999, Cell.

[53]  M. Kamphuis,et al.  Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[54]  Masaharu Akiyama,et al.  Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications , 2002, Oncogene.

[55]  A. Levin,et al.  Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). , 1997, The Journal of pharmacology and experimental therapeutics.

[56]  T. Golub.  Mining the genome for combination therapies , 2003, Nature Medicine.

[57]  P. Casey,et al.  Inhibition of purified p21 ras farnesyl:protein transferase by Cys-AAX tetrapeptides , 1990, Cell.

[58]  T. McDonnell,et al.  Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors. , 2002, The American journal of pathology.

[59]  M. Minden,et al.  Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells , 2001, Leukemia.

[60]  T. Libermann,et al.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[61]  H. Asaoku,et al.  Expressions of DNA topoisomerase I and II gene and the genes possibly related to drug resistance in human myeloma cells , 1993, British journal of haematology.

[62]  Y. Lazebnik,et al.  Caspases: enemies within. , 1998, Science.

[63]  H. Pehamberger,et al.  Chemosensitisation of malignant melanoma by BCL2 antisense therapy , 2000, The Lancet.

[64]  P. Greipp,et al.  A variant glucocorticoid receptor messenger RNA is expressed in multiple myeloma patients. , 1995, Cancer research.

[65]  C. Rao,et al.  Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. , 1999, Gastroenterology.

[66]  T. Cotter,et al.  Molecular signals in anti-apoptotic survival pathways , 2001, Leukemia.

[67]  E. Zandi,et al.  Bridging the Gap: Composition, Regulation, and Physiological Function of the IκB Kinase Complex , 1999, Molecular and Cellular Biology.

[68]  T. Rabbitts,et al.  Chromosomal translocation products engender new intracellular therapeutic technologies , 2003, Nature Medicine.

[69]  R. Stahel,et al.  Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. , 1998, British Journal of Cancer.

[70]  G D Roodman,et al.  Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. , 1992, The Journal of clinical investigation.

[71]  D. Samid,et al.  Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[72]  M. Reiss,et al.  Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice. , 2000, Cancer research.

[73]  E. Schattner,et al.  Modulation of NF-κB Activity and Apoptosis in Chronic Lymphocytic Leukemia B Cells1 , 2000, The Journal of Immunology.

[74]  M. Pabst,et al.  Removal of endotoxin from protein solutions by phase separation using Triton X-114. , 1990, Journal of immunological methods.

[75]  R. Pirker,et al.  Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[76]  M. Gleave,et al.  Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. , 1999, Cancer research.

[77]  M. Urashima,et al.  Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. , 1996, Blood.

[78]  T. Witzig,et al.  A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. , 1997, Journal of immunology.

[79]  Sujay K. Singh,et al.  Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor–κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis , 2003 .

[80]  C. Morimoto,et al.  Response patterns of purified myeloma cells to hematopoietic growth factors. , 1989, Blood.

[81]  Dylan T. Jones,et al.  Albumin activates the AKT signaling pathway and protects B-chronic lymphocytic leukemia cells from chlorambucil- and radiation-induced apoptosis. , 2003, Blood.

[82]  M. Mann,et al.  Glucosylation of Rho proteins by Clostridium difficile toxin B , 1995, Nature.

[83]  S. Sebti,et al.  Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts. , 1996, Oncogene.

[84]  J. Gutkind,et al.  Loss of PTEN expression leading to high Akt activation in human multiple myelomas. , 2000, Blood.

[85]  Guy S. Salvesen,et al.  X-linked IAP is a direct inhibitor of cell-death proteases , 1997, Nature.

[86]  G. Butti,et al.  In vivo enhanced antitumor activity of carmustine [N,N'-bis(2-chloroethyl)-N-nitrosourea] by simvastatin. , 1995, Cancer research.

[87]  G. Thorgeirsson,et al.  Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. , 2000, The American journal of cardiology.

[88]  Bin Zhang,et al.  IL-6-independent expression of Mcl-1 in human multiple myeloma , 2003, Oncogene.

[89]  R. Bataille,et al.  Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. , 2002, Blood.

[90]  V. Dixit,et al.  Caspase-9, Bcl-XL, and Apaf-1 Form a Ternary Complex* , 1998, The Journal of Biological Chemistry.

[91]  P. Johnson,et al.  Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. , 1994, Oncogene.

[92]  R. Craig,et al.  Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. , 1998, Blood.

[93]  T. Libermann,et al.  Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. , 1996, Blood.

[94]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[95]  John Calvin Reed,et al.  Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. , 1998, Blood.

[96]  N. Munshi,et al.  NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.

[97]  R. Warnke,et al.  Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. , 1987, The New England journal of medicine.

[98]  W. May,et al.  Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[99]  T. Hirano,et al.  Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors , 2000, Oncogene.

[100]  R. Bataille,et al.  IL‐6 up‐regulates Mcl‐1 in human myeloma cells through JAK / STAT rather than Ras / MAP kinase pathway , 1999, European journal of immunology.

[101]  M. Morgan,et al.  Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? , 2000 .

[102]  A. Lichtenstein,et al.  Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. , 1996, Blood.

[103]  R. Bravo,et al.  Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. , 1997, Genes & development.

[104]  L. Cantley,et al.  Rho Family GTPases Bind to Phosphoinositide Kinases (*) , 1995, The Journal of Biological Chemistry.

[105]  Joachim L. Schultze,et al.  Unbalanced Expression of Bcl-2 Family Proteins in Follicular Lymphoma: Contribution of CD40 Signaling in Promoting Survival , 1998 .

[106]  M. Rue,et al.  Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.

[107]  John Calvin Reed,et al.  bcl-2 Gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia , 1993 .

[108]  L. Pan,et al.  Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin , 2000, Leukemia.

[109]  A. Strasser,et al.  Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2 , 1990, Nature.

[110]  P Salomoni,et al.  BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[111]  Beverly S Mitchell,et al.  Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  C. Peschel,et al.  Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. , 2002, Blood.

[113]  W. Dalton,et al.  Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines , 1999 .

[114]  J. Goldstein,et al.  Polylysine and CVIM Sequences of K-RasB Dictate Specificity of Prenylation and Confer Resistance to Benzodiazepine Peptidomimetic in Vitro(*) , 1995, The Journal of Biological Chemistry.

[115]  P. Sonneveld,et al.  Modulation of multidrug-resistant multiple myeloma by cyclosporin , 1992, The Lancet.

[116]  John Calvin Reed,et al.  Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. , 1993, Cancer research.

[117]  H. Lokhorst,et al.  Risk factors for hematological malignancy in polyneuropathy associated with monoclonal gammopathy , 2001, Muscle & nerve.

[118]  D. Andrews,et al.  Bcl‐2 mutants with restricted subcellular location reveal spatially distinct pathways for apoptosis in different cell types. , 1996, The EMBO journal.

[119]  T. Stokłosa,et al.  Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[120]  B. Chaudhuri,et al.  Release of cytochrome c and decrease of cytochrome c oxidase in Bax‐expressing yeast cells, and prevention of these effects by coexpression of Bcl‐xL , 1997, FEBS letters.

[121]  S. Sebti,et al.  GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. , 1997, Cancer research.

[122]  Andrius Kazlauskas,et al.  The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase , 1995, Cell.

[123]  H. Koide,et al.  An activated mutant of R-Ras inhibits cell death caused by cytokine deprivation in BaF3 cells in the presence of IGF-I , 1997, Oncogene.

[124]  J. Baars,et al.  Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first‐line treatment in untreated multiple myeloma , 1999, British journal of haematology.

[125]  R. Craig,et al.  MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[126]  R. Bataille,et al.  Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy , 1999, Leukemia.

[127]  S. Rudikoff,et al.  Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. , 2000, Blood.

[128]  A. Arnold,et al.  Cyclin D and oncogenesis. , 1993, Current opinion in genetics & development.

[129]  R. Craig,et al.  Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. , 1997, Blood.

[130]  S. Korsmeyer,et al.  Targeting of Bcl-2 to the mitochondrial outer membrane by a COOH-terminal signal anchor sequence. , 1993, The Journal of biological chemistry.

[131]  B. Druker,et al.  Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM‐CSF, IL‐3 and steel factor and is constitutively increased by p210BCR/ABL. , 1995, The EMBO journal.

[132]  M. Gleave,et al.  Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. , 1999, Urology.

[133]  Xiaodong Wang,et al.  Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.

[134]  T. Chittenden,et al.  Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[135]  H. Kaufmann,et al.  Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. , 2000, Blood.

[136]  D. Prager,et al.  Multiple myeloma cells are protected against dexamethasone‐induced apoptosis by insulin‐like growth factors , 1997, British journal of haematology.

[137]  S. Cory,et al.  The conserved N‐terminal BH4 domain of Bcl‐2 homologues is essential for inhibition of apoptosis and interaction with CED‐4 , 1998, The EMBO journal.

[138]  C. Rudin,et al.  A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[139]  F. McCormick,et al.  Cdc42 regulates anchorage-independent growth and is necessary for Ras transformation , 1997, Molecular and cellular biology.

[140]  P. Roux,et al.  Differential Effect of Rac and Cdc42 on p38 Kinase Activity and Cell Cycle Progression of Nonadherent Primary Mouse Fibroblasts* , 2000, The Journal of Biological Chemistry.

[141]  H. Yeger,et al.  HMG–CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P–glycoprotein–expressing cells , 1996, Nature Medicine.

[142]  S. Korsmeyer,et al.  Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes. , 1992, Annual review of immunology.

[143]  I. Grigorieva,et al.  The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. , 1998, Experimental hematology.

[144]  K. Aktories.  Bacterial toxins that target Rho proteins. , 1997, The Journal of clinical investigation.

[145]  S. Bagrodia,et al.  Activation of phosphoinositide 3-kinase activity by Cdc42Hs binding to p85. , 1994, The Journal of biological chemistry.

[146]  W. May,et al.  Bcl-2 Phosphorylation Required for Anti-apoptosis Function* , 1997, The Journal of Biological Chemistry.

[147]  F. Cotter,et al.  Antisense‐mediated suppression of Bcl‐2 highlights its pivotal role in failed apoptosis in B‐cell chronic lymphocytic leukaemia , 1999, British journal of haematology.

[148]  A. Staal,et al.  The Ability of Statins to Inhibit Bone Resorption Is Directly Related to Their Inhibitory Effect on HMG‐CoA Reductase Activity , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[149]  C. Croce,et al.  Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. , 1998, Blood.

[150]  R. Gascoyne,et al.  Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. , 1994, The American journal of pathology.

[151]  C. Martínez-A,et al.  Ras Proteins: Recent Advances and New Functions , 1999 .

[152]  H. Asaoku,et al.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas , 1988, Nature.

[153]  B. Klein,et al.  Interleukin-6 in human multiple myeloma. , 1995, Blood.

[154]  R. Fonseca,et al.  Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases , 1998, British journal of haematology.

[155]  A. Krieg,et al.  Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. , 1996, Journal of immunology.

[156]  P. Lipsky,et al.  Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism. , 1997, Cancer research.

[157]  M. Wadhwa,et al.  Autologous plasma activates Akt/protein kinase B and enhances basal survival and resistance to DNA damage‐induced apoptosis in B‐chronic lymphocytic leukaemia cells , 2001, British journal of haematology.

[158]  J. Matthews,et al.  Levels of expression of the mdr1 gene and glutathione S-transferase genes 2 and 3 and response to chemotherapy in multiple myeloma. , 1992, British Journal of Cancer.

[159]  F. McCormick,et al.  An essential role for Rac in Ras transformation , 1995, Nature.

[160]  S. Korsmeyer,et al.  Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis , 1998, The EMBO journal.

[161]  J. Esteve.  Treatment Approaches for Relapsing and Refractory Multiple Myeloma , 2000, Acta oncologica.

[162]  P. Crespo,et al.  The Small GTP-binding Protein Rho Activates c-Jun N-terminal Kinases/Stress-activated Protein Kinases in Human Kidney 293T Cells , 1996, The Journal of Biological Chemistry.

[163]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[164]  E. Alnemri,et al.  Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. , 2000, Cancer research.

[165]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.

[166]  M. Kamphuis,et al.  Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein , 2003, Leukemia.

[167]  P. Meltzer,et al.  Verapamil suppresses the emergence of P‐glycoprotein‐mediated multi‐drug resistance , 1996, International journal of cancer.

[168]  K. Anderson,et al.  Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. , 2003, Blood.

[169]  R. Gascoyne,et al.  MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. , 2001, Blood.

[170]  A. Hagenbeek,et al.  Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. , 2001, The Netherlands journal of medicine.

[171]  J. Gera,et al.  Downstream effectors of oncogenic ras in multiple myeloma cells. , 2003, Blood.

[172]  H. Pehamberger,et al.  Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. , 2000, The Journal of investigative dermatology.

[173]  H. Koeffler,et al.  Methylation of the p16INK4A gene in multiple myeloma , 1998, British journal of haematology.

[174]  L. Baldini,et al.  Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14) , 2001, British journal of haematology.

[175]  N. Thornberry.  Caspases: A decade of death research , 1999, Cell Death and Differentiation.

[176]  B. Ness,et al.  Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. , 1996, Blood.

[177]  Lust,et al.  Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. , 1993, Blood.

[178]  C. Der,et al.  Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes (*) , 1995, The Journal of Biological Chemistry.

[179]  D. Green,et al.  Apoptotic cell death induced by c-myc is inhibited by bcl-2 , 1992, Nature.

[180]  T. McDonnell,et al.  Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18) , 1991, Nature.

[181]  G. Evan,et al.  Cooperative interaction between c-myc and bcl-2 proto-oncogenes , 1992, Nature.

[182]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[183]  B. Barlogie,et al.  Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. , 1995, Blood.

[184]  S. Alkan,et al.  Analysis of expression of nuclear factor κB (NF‐κB) in multiple myeloma: downregulation of NF‐κB induces apoptosis , 2001 .

[185]  P. Sonneveld,et al.  Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. , 1996, Leukemia.

[186]  C. Thompson,et al.  Bcl-2-family proteins: the role of the BH3 domain in apoptosis. , 1998, Trends in cell biology.

[187]  V. Ferrans,et al.  rac1 regulates a cytokine-stimulated, redox-dependent pathway necessary for NF-kappaB activation , 1996, Molecular and cellular biology.

[188]  J. Hermans,et al.  Bcl-2 protein expression is not related to short survival in multiple myeloma. , 1995, Leukemia.

[189]  P. L. Bergsagel,et al.  Chromosome translocations in multiple myeloma , 2001, Oncogene.

[190]  R. Bataille,et al.  Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. , 2002, Blood.

[191]  A. Bloem,et al.  Malignant Transformation of Monoclonal Gammopathy of Undetermined Significance: Cumulative Incidence and Prognostic Factors , 2001, Leukemia & lymphoma.

[192]  R. Bataille,et al.  Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells , 2002, Leukemia.

[193]  B. Klein,et al.  Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. , 1998, Blood.

[194]  B. Dörken,et al.  The IL‐6 receptor antagonist SANT‐7 overcomes bone marrow stromal cell–mediated drug resistance of multiple myeloma cells , 2001, International journal of cancer.

[195]  B. Ness,et al.  The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro , 2001, Leukemia.

[196]  P. Sonneveld,et al.  Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. , 1998, Blood.

[197]  L. Zon,et al.  Role of interleukin 6 in the growth of myeloma-derived cell lines. , 1992, Leukemia research.

[198]  P. Stacpoole,et al.  In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma. , 1991, Journal of lipid research.

[199]  R. Bataille,et al.  Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. , 2001, Blood.

[200]  D. Weiner,et al.  A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. , 1992, Blood.

[201]  L. Cantley,et al.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[202]  H. F. Barker,et al.  Normal and neoplastic human plasma cells express bcl-2 antigen. , 1991, Leukemia.

[203]  K. Schuebel,et al.  Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product , 1997, Nature.

[204]  B. Ness,et al.  Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response , 2002, Oncogene.

[205]  G. Evan,et al.  A matter of life and cell death. , 1998, Science.

[206]  M. Minden,et al.  HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis , 2002, Leukemia.

[207]  G. Freund,et al.  Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226. , 1993, Journal of immunology.

[208]  T. Greiner,et al.  Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[209]  B. Klein,et al.  Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. , 2000 .

[210]  B. Halmos,et al.  Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[211]  M. Gelb,et al.  A protein geranylgeranyltransferase from bovine brain: implications for protein prenylation specificity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[212]  A. Gewirtz,et al.  Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. , 1995, The Journal of clinical investigation.

[213]  M. Kamphuis,et al.  Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. , 2003, Blood.

[214]  A. Hall,et al.  Rho GTPases and the actin cytoskeleton. , 1998, Science.

[215]  D. Andres,et al.  Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation. , 1997, Biochemical and biophysical research communications.

[216]  D. Vordermark,et al.  Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. , 2000, Anticancer research.

[217]  M. V. Heiden,et al.  Bcl-xL Regulates the Membrane Potential and Volume Homeostasis of Mitochondria , 1997, Cell.

[218]  D. Cunningham,et al.  Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[219]  E. Feldman,et al.  GTPases and phosphatidylinositol 3-kinase are critical for insulin-like growth factor-I-mediated Schwann cell motility. , 2000, The Journal of biological chemistry.

[220]  P. Cohen,et al.  Role of Translocation in the Activation and Function of Protein Kinase B* , 1997, The Journal of Biological Chemistry.

[221]  P. Tsichlis,et al.  Differential Roles of Akt, Rac, and Ral in R-Ras-Mediated Cellular Transformation, Adhesion, and Survival , 1999, Molecular and Cellular Biology.

[222]  R. Gascoyne,et al.  Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[223]  G. Fontanini,et al.  Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[224]  P. Casey,et al.  Biochemistry of protein prenylation. , 1992, Journal of lipid research.

[225]  B. Barlogie,et al.  Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. , 2001, Blood.

[226]  B. Dörken,et al.  In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. , 2002, Blood.

[227]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[228]  C. Der,et al.  Rac regulation of transformation, gene expression, and actin organization by multiple, PAK-independent pathways , 1997, Molecular and cellular biology.

[229]  B. Barlogie,et al.  Interleukin-6 prevents dexamethasone-induced myeloma cell death. , 1994, Blood.

[230]  J. Rouault,et al.  Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells , 1994 .

[231]  R. Schreiber,et al.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.

[232]  John C Reed,et al.  Bcl-2 family proteins , 1998, Oncogene.

[233]  O. Larsson,et al.  Mevalonic Acid Is Limiting for N-Linked Glycosylation and Translocation of the Insulin-like Growth Factor-1 Receptor to the Cell Surface , 1996, The Journal of Biological Chemistry.

[234]  H. Koeffler,et al.  p53 in hematologic malignancies. , 1994, Blood.

[235]  R. Lin,et al.  A novel Cdc42Hs mutant induces cellular transformation , 1997, Current Biology.

[236]  N. Vaziri,et al.  Effect of inhibition of cholesterol synthetic pathway on the activation of Ras and MAP kinase in mesangial cells. , 1999, Biochimica et biophysica acta.

[237]  K. Keyomarsi,et al.  Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. , 1991, Cancer research.

[238]  M. Bates,et al.  Transduction of a dominant-negative H-Ras into human eosinophils attenuates extracellular signal-regulated kinase activation and interleukin-5-mediated cell viability. , 2001, Blood.

[239]  K. Anderson,et al.  CD40 ligand triggered interleukin-6 secretion in multiple myeloma. , 1995, Blood.

[240]  P. L. Bergsagel,et al.  Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[241]  L. Gierasch,et al.  Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[242]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.

[243]  Junying Yuan,et al.  Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.

[244]  K. Bhalla,et al.  Cif (Cytochrome c Efflux-Inducing Factor) Activity Is Regulated by Bcl-2 and Caspases and Correlates with the Activation of Bid , 1999, Molecular and Cellular Biology.

[245]  T. McDonnell,et al.  Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. , 1996, Journal of immunology.

[246]  B. V. Van Ness,et al.  Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan. , 2000, Blood.

[247]  A. Dabrowska,et al.  Lovastatin and tumor necrosis factor‐α exhibit potentiated antitumor effects against Ha‐ras‐transformed murine tumor Via inhibition of tumor‐induced angiogenesis , 1999, International journal of cancer.

[248]  M. Daha,et al.  Immunoglobulin production by human peripheral lymphocytes induced by anti-C3 receptor antibodies. , 1984, Journal of immunology.

[249]  M. Hibi,et al.  Vav is associated with signal transducing molecules gp130, Grb2 and Erk2, and is tyrosine phosphorylated in response to interleukin‐6 , 1997, FEBS letters.

[250]  F. Dammacco,et al.  Manumycin inhibits farnesyltransferase and induces apoptosis of drug‐resistant interleukin 6‐producing myeloma cells , 2002, British journal of haematology.

[251]  John Calvin Reed,et al.  Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. , 1994, Oncogene.

[252]  S. Korsmeyer,et al.  BCL-2 family members and the mitochondria in apoptosis. , 1999, Genes & development.

[253]  A. Strasser,et al.  E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells. , 1993, Oncogene.

[254]  M. V. van Oers,et al.  Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[255]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[256]  加藤 聖子.  Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity , 1995 .

[257]  B. Zhong,et al.  Regulation of Akt-dependent cell survival by Syk and Rac. , 2003, Blood.

[258]  R. Jove,et al.  Drug resistance in multiple myeloma: approaches to circumvention. , 1999, Seminars in oncology.

[259]  A. Namboodiri,et al.  Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. , 1997, The Journal of clinical investigation.

[260]  T. Hideshima,et al.  Molecular mechanisms of novel therapeutic approaches for multiple myeloma , 2002, Nature Reviews Cancer.

[261]  K. Fujisawa,et al.  ADP-ribosylation of rho p21 inhibits lysophosphatidic acid-induced protein tyrosine phosphorylation and phosphatidylinositol 3-kinase activation in cultured Swiss 3T3 cells. , 1993, The Journal of biological chemistry.

[262]  A. Bloem,et al.  Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines. , 1999, Leukemia research.

[263]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[264]  B. Foster,et al.  Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line , 1999, Oncogene.

[265]  E. Cesarman,et al.  Survival of leukemic B cells promoted by engagement of the antigen receptor. , 2001, Blood.

[266]  Riccardo Dalla-Favera,et al.  Mechanisms of chromosomal translocations in B cell lymphomas , 2001, Oncogene.

[267]  G. Juliusson,et al.  Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy- 3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells , 1994 .

[268]  D. L. Sokol,et al.  Nucleic acid therapeutics: state of the art and future prospects. , 1998, Blood.

[269]  L. Van Aelst,et al.  Rho GTPases and signaling networks. , 1997, Genes & development.

[270]  S. Korsmeyer,et al.  Caspase Cleaved BID Targets Mitochondria and Is Required for Cytochrome c Release, while BCL-XL Prevents This Release but Not Tumor Necrosis Factor-R1/Fas Death* , 1999, The Journal of Biological Chemistry.

[271]  Natalie A. Lissy,et al.  Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration , 1998, Nature Medicine.

[272]  B. Giepmans,et al.  Rac Activation by Lysophosphatidic Acid LPA1Receptors through the Guanine Nucleotide Exchange Factor Tiam1* , 2003, The Journal of Biological Chemistry.

[273]  L. Zon,et al.  Role of interleukin 6 in the growth of myelomaderived cell lines , 1992 .

[274]  S. Korsmeyer,et al.  bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation , 1989, Cell.

[275]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[276]  D. Grandér,et al.  Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl‐2 oncoprotein , 1995, International journal of cancer.

[277]  R. Weinstein,et al.  P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy , 1993 .

[278]  P. Georgii‐Hemming,et al.  The control of proliferation, survival and apoptosis in human multiple myeloma cells in vitro. , 1999, Current topics in microbiology and immunology.

[279]  D. Cunningham,et al.  BCL-2 antisense therapy in patients with non-Hodgkin lymphoma , 1997, The Lancet.

[280]  Tomohiko Maehama,et al.  The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate* , 1998, The Journal of Biological Chemistry.

[281]  M. Boccadoro,et al.  Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. , 1993, Blood.

[282]  T. Kinoshita,et al.  Hypermethylation of p16INK4A gene promoter during the progression of plasma cell dyscrasia , 2001, Leukemia.

[283]  G. Bokoch,et al.  Rac GTPase interacts specifically with phosphatidylinositol 3-kinase. , 1996, The Biochemical journal.

[284]  E. Cheng,et al.  Conversion of Bcl-2 to a Bax-like death effector by caspases. , 1997, Science.

[285]  G. Ahmann,et al.  Genomic abnormalities in monoclonal gammopathy of undetermined significance. , 2002, Blood.

[286]  B. Klein,et al.  p53 and RAS gene mutations in multiple myeloma. , 1992, Oncogene.

[287]  Y. Hsu,et al.  Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[288]  Spence Rk.  Emerging trends in surgical blood transfusion. , 1997 .

[289]  C. Der,et al.  Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation , 1995, Molecular and cellular biology.

[290]  P. Hawkins,et al.  Activation of the small GTP-binding proteins rho and rac by growth factor receptors. , 1995, Journal of cell science.

[291]  L. Cro,et al.  Ras oncogene mutation in multiple myeloma , 1989, The Journal of experimental medicine.

[292]  John Calvin Reed,et al.  Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. , 1996, Oncogene.

[293]  A. Hall,et al.  Rho GTPases and their effector proteins. , 2000, The Biochemical journal.

[294]  A. Neri,et al.  Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations , 2001, Oncogene.

[295]  M. Caligiuri,et al.  Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. , 2003, Blood.

[296]  M. Piris,et al.  p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. , 1994, British Journal of Cancer.

[297]  P. L. Bergsagel,et al.  The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. , 2001, Blood.

[298]  T. Kipps,et al.  Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. , 2002, Blood.

[299]  W. Dalton,et al.  Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR) , 2000, Oncogene.

[300]  W. Dalton,et al.  The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells , 2003, Leukemia.

[301]  B. V. Van Ness,et al.  Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6. , 1995, Cancer research.

[302]  J. Flores,et al.  Increased phosphoinositide 3‐kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[303]  R. Kurzrock,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and , 2022 .

[304]  J C Reed,et al.  Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. , 1998, Science.

[305]  Yi-Te Hsu,et al.  Movement of Bax from the Cytosol to Mitochondria during Apoptosis , 1997, The Journal of cell biology.

[306]  K. Anderson,et al.  Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. , 2001, Blood.

[307]  C. Craddock,et al.  Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. , 2000, Blood.

[308]  Tony Reiman,et al.  In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. , 2003, Blood.

[309]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[310]  P. Richardson,et al.  The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications , 2001, Oncogene.

[311]  W. Berdel,et al.  Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. , 2000, Blood.

[312]  D. Vaux,et al.  Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[313]  M. Boccadoro,et al.  N- and K-ras oncogenes in plasma cell dyscrasias. , 1994, Leukemia & lymphoma.

[314]  Y. Tsujimoto,et al.  Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton flux. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[315]  C. Der,et al.  Lck regulates Vav activation of members of the Rho family of GTPases , 1997, Molecular and cellular biology.

[316]  John Calvin Reed,et al.  Expression of BAX in plasma cell dyscrasias. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[317]  H. Mitsuya,et al.  Expression of Bcl-2 family of proteins in fresh myeloma cells , 1998, Leukemia.

[318]  J. Magaud,et al.  High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. , 1993, Blood.

[319]  D. P. Bentley,et al.  Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. , 1997, British Journal of Cancer.

[320]  T. Noda,et al.  bcl-2 deficiency in mice leads to pleiotropic abnormalities: accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine. , 1995, Cancer research.

[321]  K. Anderson,et al.  Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. , 1993, Blood.

[322]  R. Bataille,et al.  Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. , 2001, Blood.

[323]  W. Stec,et al.  The mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5'-nucleotidase. , 2001, Blood.

[324]  A. Trautmann,et al.  Involvement of phosphoinositide 3‐kinase and Rac in membrane ruffling induced by IL‐2 in T cells , 1998, European journal of immunology.

[325]  J. Wijdenes,et al.  Long‐term bone marrow cultured stromal cells regulate myeloma tumour growth in vitro: studies with primary tumour cells and LTBMC‐dependent cell lines , 1998, British journal of haematology.

[326]  R. Larsson,et al.  Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein. , 1994, Anti-cancer drugs.

[327]  G. Butti,et al.  Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells. , 1992, Cancer research.

[328]  P. Georgii‐Hemming,et al.  Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. , 1996, Blood.

[329]  J. Schrader,et al.  Activation of Rac-1, Rac-2, and Cdc42 by hemopoietic growth factors or cross-linking of the B-lymphocyte receptor for antigen. , 2002, Blood.

[330]  R. Bataille,et al.  Mcl‐1 and Bcl‐xL are co‐regulated by IL‐6 in human myeloma cells , 1999, British journal of haematology.

[331]  J C Reed,et al.  Mitochondria and apoptosis. , 1998, Science.

[332]  W. Kuehl,et al.  Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. , 2001, Blood.

[333]  B. Barlogie,et al.  Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. , 1999, Blood.

[334]  G. Kroemer,et al.  Chemotherapy: targeting the mitochondrial cell death pathway , 2002, Oncogene.

[335]  H. Kalthoff,et al.  Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. , 1998, International journal of oncology.

[336]  R. Weiss,et al.  Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27Kip1 and P13 kinase. , 1999, Journal of the American Society of Nephrology : JASN.

[337]  G. Prendergast,et al.  Critical role of Rho in cell transformation by oncogenic Ras. , 1995, Oncogene.

[338]  F. Zhan,et al.  Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. , 2003, Blood.

[339]  M. Taniwaki,et al.  The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. , 1997, Blood.

[340]  S. Harris,et al.  Stimulation of bone formation in vitro and in rodents by statins. , 1999, Science.

[341]  Y. Gazitt,et al.  Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells. , 2003, Blood.

[342]  K. Kaibuchi,et al.  Identification of a Putative Target for Rho as the Serine-Threonine Kinase Protein Kinase N , 1996, Science.

[343]  R. Hawley,et al.  Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL. , 1995, Cancer research.

[344]  P. Heinrich,et al.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. , 1998, The Biochemical journal.

[345]  J. Gołąb,et al.  Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice. , 1998, European journal of cancer.

[346]  M. Rowe,et al.  Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells , 2002, Oncogene.

[347]  I. Gojo,et al.  The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[348]  D. Chauhan,et al.  Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma , 2001, Oncogene.

[349]  A. Ashworth,et al.  An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1 , 1995, Science.

[350]  Y. Tsujimoto,et al.  Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[351]  S. Narumiya,et al.  Clostridium botulinum C3 ADP-ribosyltransferase gene. Cloning, sequencing, and expression of a functional protein in Escherichia coli. , 1991, The Journal of biological chemistry.

[352]  K. Anderson,et al.  The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. , 2003, Blood.

[353]  S. Chen,et al.  Diva, a Bcl-2 Homologue that Binds Directly to Apaf-1 and Induces BH3-independent Cell Death* , 1998, The Journal of Biological Chemistry.

[354]  Guido Kroemer,et al.  Mitochondrial control of cell death , 2000, Nature Medicine.

[355]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[356]  F. McCormick,et al.  A role for Rho in Ras transformation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[357]  M. Lewis,et al.  Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo * , 1997, The Journal of Biological Chemistry.

[358]  J. Bertoglio,et al.  Inhibition of superoxide production in B lymphocytes by rac antisense oligonucleotides. , 1992, The Journal of biological chemistry.

[359]  H. Pahl.  Activators and target genes of Rel/NF-κB transcription factors , 1999, Oncogene.

[360]  S. Rudikoff,et al.  Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. , 2002, Blood.

[361]  David G. Kirsch,et al.  Caspase-3-dependent Cleavage of Bcl-2 Promotes Release of Cytochrome c * , 1999, The Journal of Biological Chemistry.

[362]  M. Wasik,et al.  Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. , 2001, Cancer research.

[363]  M. White,et al.  Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. , 1998, Science.

[364]  T. Mohanakumar,et al.  Characterization of HDJ-2, a human 40 kD heat shock protein. , 1998, The international journal of biochemistry & cell biology.

[365]  R. Lemieux,et al.  Role of bcl-X(L) in the control of apoptosis in murine myeloma cells. , 1996, Cancer research.

[366]  P. Meltzer,et al.  Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[367]  P. L. Bergsagel,et al.  Multiple myeloma: increasing evidence for a multistep transformation process. , 1998, Blood.

[368]  G. Leca,et al.  [39] Inhibition of Rac function using antisense oligonucleotides , 1995 .

[369]  A. Baldwin,et al.  THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .

[370]  O. Larsson,et al.  Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc. , 1997, Glycobiology.

[371]  John Calvin Reed,et al.  Cytochrome c: Can't Live with It—Can't Live without It , 1997, Cell.

[372]  L. Larsson,et al.  Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. , 1992, Blood.

[373]  K. Anderson,et al.  Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[374]  P. Crespo,et al.  The small GTP-binding proteins Rac1 and Cdc42regulate the activity of the JNK/SAPK signaling pathway , 1995, Cell.

[375]  John Calvin Reed,et al.  Identification of a p53-dependent negative response element in the bcl-2 gene. , 1994, Cancer research.

[376]  P. L. Bergsagel,et al.  Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. , 2000, Blood.

[377]  P. Warne,et al.  R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways , 1997, Current Biology.

[378]  L. Corcos,et al.  Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies , 2000, Leukemia.

[379]  P. Warne,et al.  Role of Phosphoinositide 3-OH Kinase in Cell Transformation and Control of the Actin Cytoskeleton by Ras , 1997, Cell.